ARCHIVES

FDA Staff Failed To Explain Approval Standards, Correct Misconceptions.

This article is from The Cancer Letter archive.

Vol. 33 No. 14 | April 13, 2007

Download PDF Visit The Full Archive

Related Articles

ASCO Annual Meeting: New Therapeutic Approaches To Breast Cancer Highlighted

June 25, 2004

ODAC Prefers Three-Hour Taxol Infusion. Says Data Dosage Still Uncertain

October 1, 1993

BMS Agent Yervoy Received FDA Approval for Metastatic Melanoma

March 25, 2011

Funding Opportunities

October 25, 2002

Greatest Need Of Cancer Care Givers: “Will to Work Together,” ACCC President Anderson Says

August 15, 1986

Avastin Improves PFS In Advanced Breast Cancer

April 29, 2005